不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:(18)F-FDG PET/CT in the diagnosis and treatment of atypical extensive skin lesions in extranodal natural killer/T-cell lymphoma, nasal type: a case report.
(18)F-FDG PET/CT in the diagnosis and treatment of atypical extensive skin lesions in extranodal natural killer/T-cell lymphoma, nasal type: a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们报告一例60岁男性患者,6个月前无明显诱因于左上肢出现散在红斑和丘疹。最初,患者接受了多种皮肤病的评估,包括湿疹和银屑病,同时也接受了潜在恶性肿瘤如皮肤淋巴瘤或结节病的评估,但未作出明确诊断。随着时间推移,患者症状进展,表现为全身性红斑、丘疹、局部瘙痒和疼痛。皮损的组织病理学检查诊断为结外NK/T细胞淋巴瘤,鼻型(ENKTCL-NT)。随后,患者接受18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)进行分期,结果显示广泛分布的代谢活跃病灶,主要累及四肢和臀部的皮肤及皮下组织。患者接受了P-GEMOX(吉西他滨、奥沙利铂和培门冬酶)序贯治疗,并在六个治疗周期后接受了临床检查及随访全身18F-FDG PET/CT。治疗后PET/CT显示鼻腔或皮肤无异常18F-FDG摄取,确认临床完全缓解。本病例突出了18F-FDG PET/CT在临床实践中对ENKTCL-NT初始分期和治疗反应评估的重要作用。
We report a case of a 60-year-old man who developed scattered erythema and papules on his left upper limb without any apparent cause 6 months ago. Initially, the patient underwent evaluations for various dermatological conditions, including eczema and psoriasis, while also being assessed for potential malignancies such as cutaneous lymphoma or sarcoidosis, but no definitive diagnosis was made. Over time, the patient's symptoms progressed, presenting as generalized erythema, papules, localized itching, and pain. A histopathological examination of the lesions diagnosed it as extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT).
Subsequently, the patient was referred for staging via 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), which revealed a widespread pattern of metabolically active lesions primarily affecting the skin and subcutaneous tissue of the limbs and buttocks.
The patient received sequential treatment with P-GEMOX (gemcitabine, oxaliplatin, and pegaspargase) and underwent clinical examination and follow-up whole-body 18 F-FDG PET/CT after six treatment cycles. The post-treatment PET/CT showed no abnormal 18 F-FDG uptake in the nasal cavity or skin, confirming clinical complete remission.
Our case highlights the significant role of 18 F-FDG PET/CT in clinical practice for initial staging and treatment response assessment of ENKTCL-NT.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。